J. Mallolas

发表

A New Multidisciplinary Home Care Telemedicine System to Monitor Stable Chronic Human Immunodeficiency Virus-Infected Patients: A Randomized Study

E. Gómez, Felipe García, J. Miro, 2011, PloS one.

High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir

T. Pumarola, J. Gatell, A. León, 2005, AIDS.

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy.

J. Mallolas, E. Martinez, R. Casamitjana, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

50 BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN FOR THE TREATMENT OF HCV/HIV CO-INFECTED PATIENTS: END OF TREATMENT (WEEK 48) INTERIM RESULTS

C. Cooper, J. Mallolas, S. Pol, 2012 .

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

J. Mallolas, C. Quereda, F. Pulido, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir‐boosted saquinavir. The CIVSA Study *

M. Arnedo, T. Pumarola, J. Mallolas, 2007, HIV medicine.

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

M. Bickel, P. Cahn, J. Mallolas, 2019, Journal of acquired immune deficiency syndromes.

Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes.

J. Gatell, J. Mallolas, J. Bisbe, 1988, Reviews of infectious diseases.

Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study

D. Podzamczer, B. Clotet, J. Gatell, 2009, Journal of acquired immune deficiency syndromes.

Pharmacokinetic interaction between rifampicin and ritonavir‐boosted atazanavir in HIV‐infected patients *

Á. Soriano, J. Mallolas, M. Nomdedeu, 2007, HIV medicine.

Intrathoracic fat in HIV‐infected patients

A. León, J. Mallolas, M. Larrousse, 2006, HIV medicine.

Eradication of hepatitis C virus and non‐liver‐related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection

C. Tural, J. Mallolas, M. Crespo, 2017, Hepatology.

Effi cacy and safety of grazoprevir ( MK-5172 ) and elbasvir ( MK-8742 ) in patients with hepatitis C virus and HIV co-infection ( C-EDGE CO-INFECTION ) : a non-randomised , open-label trial

C. Katlama, M. Saag, J. Rockstroh, 2015 .

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

C. Katlama, M. Saag, J. Rockstroh, 2015, The lancet. HIV.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

J. Mallolas, S. Pol, A. Howe, 2013, The Lancet. Infectious diseases.

Once-Daily Regimen of Saquinavir, Ritonavir, Didanosine, and Lamivudine in HIV-Infected Patients With Standard Tuberculosis Therapy (TBQD Study)

Á. Soriano, J. Gatell, J. Mallolas, 2005, Journal of acquired immune deficiency syndromes.

A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

D. Podzamczer, B. Clotet, J. Miro, 2009, Journal of acquired immune deficiency syndromes.

Influence of treatment with zidovudine (ZDV) on the long-term survival of AIDS patients.

J. Miro, J. Gatell, J. Mallolas, 1992, Journal of acquired immune deficiency syndromes.

Analysis of factors influencing the outcome and development of septic metastasis or relapse in Salmonella bacteremia.

J. Miro, J. Gatell, J. Mallolas, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection?

J. Mallolas, M. Laguno, S. Mauss, 2005, HIV medicine.

A need for implementation science to optimise the use of evidence-based interventions in HIV care: A systematic literature review

H. Jessen, C. Katlama, J. Mallolas, 2019, PloS one.

A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients.

J. Miro, J. Gatell, J. Mallolas, 2007, Revista clinica espanola.

Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients

J. Mallolas, M. Laguno, J. Navarro, 2017, The Journal of antimicrobial chemotherapy.

A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care

P. Marcellin, B. Bacon, J. Mallolas, 2013, Hepatology.

O63 EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/− RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY

J. Mallolas, S. Pol, O. Shibolet, 2014 .

The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients

Ò. Miró, A. León, J. Mallolas, 2006, Antiviral therapy.

Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz.

J. Gatell, A. Rousaud, J. Blanch, 2001 .

Full blood count values as a predictor of poor outcome of pneumonia among HIV-infected patients

J. Mallolas, N. Saubí, Timothy D McHugh, 2018, BMC Infectious Diseases.

Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.

B. Clotet, J. Mallolas, M. Crespo, 2012, The Journal of infection.

Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.

J. Mallolas, V. Soriano, M. Pérez-Elías, 2009, Enfermedades infecciosas y microbiologia clinica.

[Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1].

J. Mallolas, I. Oyagüez, M. Casado, 2009, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

Randomized trial comparing pegylated interferon α‐2b versus pegylated interferon α‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

C. Tural, J. Gatell, J. Mallolas, 2009, Hepatology.

A prospective study of the risk of tuberculosis among HIV‐infected patients

D. Podzamczer, J. Miro, J. Gatell, 1993, AIDS.

Characteristics of tuberculosis in HIV-infected patients: a case-control study.

J. Miro, J. Gatell, J. Mallolas, 1988, AIDS.

Patterns of resistance of Mycobacterium tuberculosis in Spanish patients infected with human immunodeficiency virus type 1 (HIV-1).

J. Miro, J. Gatell, J. Mallolas, 1995, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Fixed-dose combination of abacavir, lamivudine and zidovudine for HIV therapy

J. Mallolas, A. Milinkovic, 2007 .

Clinical presentation of acute coronary syndrome in HIV infected adults: a retrospective analysis of a prospectively collected cohort.

Ò. Miró, J. Mallolas, E. Martinez, 2011, European journal of internal medicine.

Observational cohort study of rilpivirine (RPV) utilization in Europe

C. Leen, A. Mocroft, R. Paredes, 2022, AIDS Research and Therapy.

Skeletal muscle studies in patients with HIV-related wasting syndrome

Ò. Miró, J. Mallolas, J. Grau, 1997, Journal of the Neurological Sciences.

Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study

Felipe García, J. Miro, J. Mallolas, 2020, AIDS.

Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy.

J. Miro, J. Gatell, J. Mercader, 1990, AIDS.

Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz

J. Gatell, A. Rousaud, J. Blanch, 2001, Journal of acquired immune deficiency syndromes.

Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.

J. Mallolas, M. Crespo, C. Quereda, 2011, The Journal of antimicrobial chemotherapy.

Analysis of Prognostic Factors in 274 Consecutive Episodes of Pseudomonas aeruginosa Bacteremia1

J. Miro, J. Gatell, J. Mallolas, 1991 .

Analysis of prognostic factors in 274 consecutive episodes of Pseudomonas aeruginosa bacteremia.

J. Miro, J. Gatell, J. Mallolas, 1991, Antibiotics and chemotherapy.

Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study

Á. Soriano, J. Mallolas, M. Laguno, 2022, Infectious Diseases and Therapy.

Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.

C. Tural, J. Mallolas, C. Quereda, 2013, Journal of hepatology.

Pegylated IFN-α2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV

J. Mallolas, M. Laguno, 2008, Expert review of anti-infective therapy.

Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations

C. Tural, J. Miro, V. Soriano, 2004, Journal of viral hepatitis.

Antibiotic prophylaxis in non-cardiac thoracic surgery: cefazolin versus placebo.

J. Gimferrer, J. Miro, J. Gatell, 1991, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Long term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in HCV-HIV coinfected patients.

J. Mallolas, E. Martinez, J. Blanco, 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients

Á. Soriano, J. Mallolas, M. Laguno, 2022, Infection.

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers

Ò. Miró, J. Gatell, J. Mallolas, 2019, PloS one.

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.

J. Gatell, J. Mallolas, E. Martinez, 2014, The Journal of antimicrobial chemotherapy.

Pharmacokinetic Study of Dual Therapy With Raltegravir 400 mg Twice Daily and Darunavir/Ritonavir 800/100 mg Once Daily in HIV-1–Infected Patients

J. Gatell, J. Mallolas, E. Martinez, 2013, Therapeutic drug monitoring.

Zidovudine-induced nail pigmentation.

J. Mallolas, T. Castel, J. Gatell, 1988, Archives of dermatology.

J. Mallolas, E. Condom, E. Cabré, 1998, American Journal of Gastroenterology.

Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis.

J. Mallolas, E. Condom, E. Cabré, 1996, Gut.

Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice.

J. Mallolas, E. Ferrer, E. Pedrol, 2012, AIDS research and human retroviruses.

Abacavir does not Influence the Rate of Virological Response in HIV–HCV-Coinfected Patients Treated with Pegylated Interferon and Weight-Adjusted Ribavirin

J. Gatell, J. Mallolas, M. Laguno, 2008, Antiviral therapy.

Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts *

J. Montaner, B. Clotet, E. Negredo, 2008, HIV medicine.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

Andrew Phillips, Esteban Martínez, Xavier Carné, 2001, AIDS.

Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients

B. Clotet, J. Mallolas, J. Macías, 2012, HIV clinical trials.

Depressive Symptoms after Initiation of Interferon Therapy in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C

Felipe García, J. Miro, J. Gatell, 2004, Antiviral therapy.

COVID-19 in patients with HIV: clinical case series

Felipe García, Á. Soriano, J. Miro, 2020, The Lancet HIV.

TRIZAL study: switching from successful HAART to TrizivirTM (abacavir‐lamivudine‐zidovudine combination tablet): 48 weeks efficacy, safety and adherence results

B. Gazzard, C. Katlama, A. Lazzarin, 2003, HIV medicine.

Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome

Á. Soriano, J. Miro, J. Mallolas, 2020, International Journal of Infectious Diseases.

Metabolic and Immunological Effects of Antiretroviral Agents in Healthy Individuals Receiving Post-Exposure Prophylaxis

Felipe García, G. Mestre, M. Plana, 2001, Antiviral therapy.

Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy

E. Negredo, J. Mallolas, J. Blanco, 2022, International journal of molecular sciences.

Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study.

J. Gatell, A. León, J. Mallolas, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors.

J. Gatell, J. Mallolas, C. Tortajada, 1997, AIDS.

Do ART and Chemsex Drugs Get Along? Potential Drug–Drug Interactions in a Cohort of People Living with HIV Who Engaged in Chemsex: A Retrospective Observational Study

L. Miquel, J. Blanch, J. Mallolas, 2022, Infectious Diseases and Therapy.

Erythema nodosum and Q fever.

J. Mallolas, I. Conget, J. Mensa, 1987, Archives of dermatology.

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice – Vie-KinD study

J. Mallolas, M. Laguno, J. Losa, 2019, PloS one.

Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.

J. Gatell, J. Mallolas, E. Martinez, 2016, Journal of Antimicrobial Chemotherapy.

Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine

T. Pumarola, J. Gatell, A. León, 2005, AIDS.

Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults

Felipe García, J. Miro, J. Gatell, 2004, The Lancet.

Bictegravir/emtricitabine/tenofovir Alafenamide for the Treatment of People Living with HIV

J. Mallolas, 2022, Infectious Diseases.

Acute and chronic graft‐vs‐host reaction in skin: report of two cases *

A. Grañena, J. Mallolas, E. Feliú, 1980, The British journal of dermatology.

MRI signal changes of the bone marrow in HIV-infected patients with lipodystrophy: correlation with clinical parameters

J. Mallolas, A. Milinkovic, S. Vidal-Sicart, 2011, Skeletal Radiology.

Estado actual de la hepatitis aguda C

J. Mallolas, E. Martinez, J. Blanco, 2011 .

Septic arthritis in heroin addicts.

J. Miro, J. Gatell, J. Mallolas, 1991, Seminars in arthritis and rheumatism.

Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study

X. Forns, J. Blanch, J. Mallolas, 2021, Infectious Diseases and Therapy.

Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study.

J. J. de la Cruz, V. Soriano, M. Vogel, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients.

J. Gatell, J. Mallolas, E. Martinez, 2012, AIDS research and human retroviruses.

Phylogenetic analysis of an epidemic outbreak of acute hepatitis C in HIV-infected patients by ultra-deep pyrosequencing.

X. Forns, F. González-Candelas, J. Mallolas, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[Varicella pneumonia in adults infected by HIV-1. Presentation of 2 cases].

M. Sans, J. Mallolas, E. Soriano, 1994, Enfermedades infecciosas y microbiologia clinica.

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Miguel Ángel Martínez, D. Podzamczer, J. Mallolas, 2021, The Lancet HIV.

Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy.

J. Miro, J. Mallolas, M. García-Viejo, 2000, AIDS.

Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003).

Felipe García, M. Plana, M. Arnedo, 2006, Enfermedades infecciosas y microbiologia clinica.

Specific cutaneous manifestations of Waldenström's macroglobulinaemia. A report of two cases *

E. Montserrat, J. Mallolas, E. Feliú, 1982, The British journal of dermatology.

Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review.

J. Miro, J. Gatell, J. Mallolas, 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Diagnostic value of serum antibody and antigen detection in heroin addicts with systemic candidiasis.

J. Miro, J. Mallolas, J. Bisbe, 1989, Reviews of infectious diseases.

Prognostic factors influencing the outcome in pneumocystis carinii pneumonia in patients with AIDS.

R. Rodríguez-Roisín, J. Miro, J. Gatell, 1995, Thorax.

Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

D. Podzamczer, J. Mallolas, J. Caylà, 2016, Enfermedades infecciosas y microbiologia clinica.

High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors.

J. Gatell, J. Mallolas, E. Martinez, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS.

D. Podzamczer, B. Clotet, J. Mallolas, 1990, The Journal of infection.

Vertebral arch tuberculosis in two human immunodeficiency virus-seropositive heroin addicts.

J. Mallolas, A. Trilla, E. Soriano, 1988, Archives of internal medicine.

Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

D. Podzamczer, J. Mallolas, J. Caylà, 2016, Enfermedades infecciosas y microbiologia clinica.

The effectiveness and tolerability of imiquimod suppositories to treat extensive intra-anal high-grade squamous intraepithelial lesions/warts in HIV-infected individuals

Ross D. Cranston, J. Ordi, J. Mallolas, 2019, International journal of STD & AIDS.

Efficacy of octreotide in the management of chronic diarrhoea in AIDS.

B. Clotet, J. Romeu, G. Sirera, 1991, AIDS.

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients : A randomized controlled comparison with zidovudine monotherapy

C. Katlama, S. Staszewski, M. Johnson, 1996 .

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

Roger Paredes, Esteban Martinez, Bonaventura Clotet, 2018, The Journal of antimicrobial chemotherapy.

Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy

J. Gatell, A. León, J. Mallolas, 2006, AIDS.

Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord

D. Raben, J. Rockstroh, F. Dabis, 2015, BMC Infectious Diseases.

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

C. Katlama, S. Staszewski, C. Loveday, 1996, JAMA.

Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients.

J. Gatell, J. Sánchez-Tapias, A. León, 2008, AIDS research and human retroviruses.

Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin

J. Gatell, J. Sánchez-Tapias, A. León, 2007, Journal of acquired immune deficiency syndromes.

Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell Count

Felipe García, G. Mestre, M. Plana, 2004, Journal of acquired immune deficiency syndromes.

A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

Felipe García, A. León, J. Mallolas, 2016, The Journal of antimicrobial chemotherapy.

Once-daily antiretroviral therapy: Spanish Consensus Statement.

D. Podzamczer, J. Mallolas, J. Ena, 2005, The Journal of antimicrobial chemotherapy.

Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?

J. Mallolas, V. Soriano, L. López-Cortés, 2005, Enfermedades infecciosas y microbiologia clinica.

Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine

J. Mallolas, M. Laguno, S. Mauss, 2004, Hepatology.

Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study.

J. Miro, J. Gatell, C. Codina, 2008, AIDS research and human retroviruses.

Intravenous cidofovir for compassionate use in AIDS patients with cytomegalovirus retinitis. Spanish Cidofovir Study Group.

J. Mallolas, J. Berenguer, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pegylated interferon a 2 a plus ribavirin versus pegylated interferon a 2 b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

C. Tural, J. Mallolas, C. Quereda, 2009 .

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients

A. León, J. Mallolas, E. Martinez, 2004, AIDS.

Incidence and Risk Factors for Mitochondrial Toxicity in Treated HIV/HCV-Coinfected Patients

Felipe García, J. Miro, J. Gatell, 2005, Antiviral therapy.

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

C. Tural, J. Mallolas, C. Quereda, 2009, The Journal of antimicrobial chemotherapy.

Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data

Á. Soriano, J. Mallolas, J. Blanco, 2021, Infectious Diseases and Therapy.

Pegylated interferon a 2a plus ribavirin versus pegylated interferon a 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

C. Tural, J. Mallolas, C. Quereda, 2009 .

[A comparative study of the clinical and histological characteristics between classic nemaline myopathy and that associated with the human immunodeficiency virus].

Ò. Miró, J. Mallolas, M. García-Carrasco, 1995, Medicina clinica.

Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.

J. Mallolas, J. Blanco, X. Carné, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

H. Teppler, Valerie Teal, J. Mallolas, 2019, Journal of acquired immune deficiency syndromes.

Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

C. Tural, J. Mallolas, C. Quereda, 2009, Hepatology.

A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity

M. Plana, J. Miro, J. Gatell, 2018, AIDS.

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.

D. Podzamczer, J. Gatell, J. Mallolas, 2015, The Lancet. Infectious diseases.

Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis

A. Cruceta, J. Miro, A. León, 2017, The Journal of antimicrobial chemotherapy.

Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients

Ò. Miró, A. León, J. Mallolas, 2020, Frontiers in Genetics.

A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

Felipe García, A. León, J. Mallolas, 2016, The Journal of antimicrobial chemotherapy.

Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations

T. Pumarola, J. Gatell, A. León, 2006, AIDS.

An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide–induced cholestasis

J. Mallolas, M. Laguno, M. Martínez-Rebollar, 2021, Antiviral therapy.

Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis.

D. Podzamczer, M. Lejeune, Felipe García, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Intracranial tuberculomas in patients with AIDS.

E. Tolosa, J. Miro, J. Mallolas, 1991, AIDS.

Overview of SARS-CoV-2 infection in adults living with HIV

Á. Soriano, J. Miro, J. Mallolas, 2021, The Lancet HIV.

Serum levels of β2-microglobulin, neopterin, TNF-α and soluble receptors of TNF-α and interleukin-2 in intravenous drug abusers according to HIV-1 status and stage of the HIV-1 infection

Felipe García, J. Miro, J. Gatell, 1998 .

Immunological and virological findings in a patient with exceptional post-treatment control: a case report.

R. Paredes, M. Plana, J. Miro, 2022, The lancet. HIV.

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

Ignacio Conget, Andrew Phillips, Esteban Martínez, 2001, The Lancet.

P0887 : C-edge co-infected: phase 3 study of grazoprevir/elbasvir in patients with HCV/HIV

C. Katlama, M. Saag, S. Klopfer, 2015 .

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Tolerability of integrase inhibitors in a real-life setting

J. Gatell, J. Blanch, J. Mallolas, 2017, The Journal of antimicrobial chemotherapy.

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).

D. Podzamczer, B. Clotet, J. Gatell, 2014, Enfermedades infecciosas y microbiologia clinica.

Clinical Characteristics and Outcome of Bloodstream Infections in HIV-Infected Patients with Cancer and Febrile Neutropenia: A Case–Control Study

J. Esteve, Felipe García, Á. Soriano, 2021, Infectious Diseases and Therapy.

Chemsex Practices in PrEP: Beyond Addiction and Risk Toward a Healthy Sex Life—Baseline Experiences from a Hospital-Based PrEP Program in Barcelona, Spain

L. Miquel, J. Blanch, J. Mallolas, 2022, AIDS and Behavior.

Vulnerability Conditions in a Cohort of Men Who Have Sex with Men Who Engage in Chemsex in Barcelona City: a Cross-Sectional Study

L. Miquel, J. Blanch, J. Mallolas, 2022, Sexuality Research and Social Policy.

Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.

J. Miro, J. Gatell, J. Mallolas, 1993, AIDS.

Pharmacokinetic Study of Saquinavir 500 mg Plus Ritonavir (1000/100 mg Twice a Day) in HIV-Positive Pregnant Women

J. Mallolas, E. Martinez, J. Blanco, 2011, Therapeutic Drug Monitoring.

Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

D. Podzamczer, J. Mallolas, J. Losa, 2021, Trials.

Evolution of Risk Behaviors, Sexually Transmitted Infections and PrEP Care Continuum in a Hospital-Based PrEP Program in Barcelona, Spain: A Descriptive Study of the First 2 Years’ Experience

J. Mallolas, J. Blanco, M. Laguno, 2022, Infectious Diseases and Therapy.

PrEP program experience in a hospital HIV unit. Description of baseline user profile and identification of opportunities for improvement.

J. Mallolas, E. Martinez, J. Blanco, 2021, Enfermedades infecciosas y microbiologia clinica.

Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis.

J. Mallolas, M. Górgolas, A. Cabello, 2020, Gastroenterologia y hepatologia.

Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis

J. Mallolas, M. Górgolas, A. Cabello, 2022, Gastroenterología y Hepatología (English Edition).

Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues.

A. León, J. Mallolas, E. Martinez, 2007, The Journal of antimicrobial chemotherapy.

Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir / ritonavircontaining ritonavircontaining ritonavircontaining therapy free of thymidine analogues

A. León, J. Mallolas, E. Martinez, 2007 .

Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, 1982 to 2020

E. Fernández, J. Mallolas, J. Blanco, 2023, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19

Á. Soriano, J. Mallolas, M. Laguno, 2022, Scientific Reports.

Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review

D. Podzamczer, J. Miro, D. Giralt, 2021, BMC Public Health.

[Acute outbreak of hepatitis C in human immunodeficiency virus-infected patients].

J. Gatell, J. Mallolas, E. Martinez, 2015, Enfermedades infecciosas y microbiologia clinica.

Acquisition of resistant microorganisms and infections in HIV-infected patients admitted to the ICU

Á. Soriano, J. Mallolas, J. Nicolás, 2014, European Journal of Clinical Microbiology & Infectious Diseases.

Incidence and causes of death in HIV‐infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area

A. León, J. Mallolas, M. Laguno, 2007, HIV medicine.

Antineutrophil antibodies associated with ulcerative colitis interact with the antigen(s) during the process of apoptosis

J. Mallolas, E. Rius, E. Cabré, 2000, Gut.

Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.

Felipe García, M. Plana, T. Gallart, 2008, The Journal of antimicrobial chemotherapy.

Predictors of Tonsillar Tissue HIV-1 Viral Burden at Baseline and after 1 Year of Antiretroviral Therapy

Felipe García, G. Mestre, M. Plana, 2002, Antiviral therapy.

Lymphoid tissue viral burden and duration of viral suppression in plasma

Felipe García, M. Arnedo, C. Gil, 2001, AIDS.

Transmission of HIV-1 from an obstetrician to a patient during a caesarean section

M. Arnedo, T. Pumarola, J. Gatell, 2006, AIDS.

Influence of environmental temperature on incidence of indinavir-related nephrolithiasis.

J. Miro, J. Gatell, J. Mallolas, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor

Felipe García, M. Arnedo, T. Pumarola, 2005, AIDS.

A 24-week pilot study of dual maintenance therapy with raltegravir plus lamivudine.

M. Plana, J. Blanch, J. Mallolas, 2019, AIDS.

Impact of Prior Virological Failure and Nucleos(t)ide Genotypic Resistance Mutations on the Efficacy of Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir

D. Podzamczer, J. Mallolas, E. Martinez, 2015, Antiviral therapy.

Cholangitis and pulmonary nodules in a clinical presentation of syphilis in an HIV-infected patient

Felipe García, I. Vollmer, J. Mallolas, 2019, International journal of STD & AIDS.

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.

D. Podzamczer, B. Clotet, J. Romeu, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³.

Felipe García, M. Plana, M. Arnedo, 2013, AIDS research and human retroviruses.

Comparison of Metabolic Abnormalities and Clinical Lipodystrophy 48 Weeks After Switching from HAART to Trizivir™ Versus Continued HAART: The Trizal Study

M. Johnson, J. Mallolas, N. Clumeck, 2003, HIV clinical trials.

Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy.

J. Mallolas, E. Ribera, M. Márquez, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

D. Podzamczer, J. Gatell, J. Mallolas, 2010, AIDS.

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients

J. Mallolas, J. Macías, S. Moreno, 2010, Journal of the International AIDS Society.

High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients

J. Mallolas, Y. Pacheco, F. Vidal, 2020, EBioMedicine.

Comparación de tres métodos de cálculo de adherencia en pacientes con tratamiento antirretroviral

Felipe García, J. Miro, J. Mallolas, 2002 .

Noninvasive Diagnosis of Hepatic Fibrosis in HIV/HCV-Coinfected Patients

J. Miro, J. Gatell, A. León, 2007, Journal of acquired immune deficiency syndromes.

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.

A. Cruceta, J. Mallolas, M. Laguno, 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[Chondrocostal and chondrosternal tuberculosis in 2 heroin addicts infected with the human immunodeficiency virus].

J. Miro, J. Gatell, J. Mallolas, 1989, Medicina clinica.

[Resurrection of tuberculosis].

J. Mallolas, E. Soriano, 1988, Medicina clínica (Ed. impresa).

[Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. An analysis of 67 cases with a study of the prognostic factors].

J. Miro, J. Gatell, J. Mallolas, 1990, Medicina clinica.

Differences between HIV‐infected and uninfected adults in the contributions of smoking, diabetes and hypertension to acute coronary syndrome: two parallel case–control studies

J. Mallolas, M. Laguno, M. Junyent, 2013, HIV medicine.

PHARMACOKINETICS OF FALDAPREVIR AND ANTIRETROVIRALS IN PATIENTS WITH HIV/HCV CO-INFECTION

D. Dieterich, J. Rockstroh, J. Mallolas, 2014 .

IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status

J. Mallolas, E. Rodríguez-Gallego, E. Ruiz-Mateos, 2019, Scientific Reports.

Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients.

Felipe García, J. Miro, J. Gatell, 2002, Journal of acquired immune deficiency syndromes.

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

D. Podzamczer, J. Gatell, P. Reiss, 2003, AIDS.

Darunavir Stands Up as Preferred HIV Protease Inhibitor.

J. Mallolas, 2017, AIDS reviews.

Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

C. Tural, J. Mallolas, M. Crespo, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy

J. Mallolas, E. Martinez, N. Saubí, 2019, BMC Infectious Diseases.

Subacute cerebellar syndrome as the first manifestation of AIDS dementia complex

E. Tolosa, J. Miro, J. Mallolas, 1990, Acta neurologica Scandinavica.

Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy

D. Podzamczer, J. Gatell, J. Mallolas, 2016, HIV clinical trials.

Clinicoimmunological progression and response to treatment of long-term nonprogressor HIV-hepatitis C virus-coinfected patients.

Felipe García, M. Plana, T. Gallart, 2007, AIDS research and human retroviruses.

Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy

D. Podzamczer, J. Gatell, J. Mallolas, 2017, HIV clinical trials.

Detection of unknown cases of human immunodeficiency virus infection in emergency departments: a utopian ideal?

J. Mallolas, A. Ugarte, 2021, Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias.

Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.

J. Mallolas, M. Laguno, M. Londoño, 2019, Gastroenterologia y hepatologia.

Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia

J. Mallolas, M. Laguno, M. Londoño, 2019, Gastroenterología y Hepatología (English Edition).

Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection.

J. Mallolas, X. Carné, J. Gatell, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Impact of coronavirus disease 2019 epidemics on prevention and care for HIV and other sexually transmitted infections

J. Miro, J. Mallolas, E. Martinez, 2022, AIDS.

Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy

B. Gazzard, M. Moroni, C. Katlama, 2003, AIDS (London).

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection

D. Podzamczer, J. Mallolas, C. Orrell, 2017, HIV clinical trials.

Pharmacogenetics of Efficacy and Safety of HCV Treatment in HCV-HIV Coinfected Patients: Significant Associations with IL28B and SOCS3 Gene Variants

M. Arnedo, J. Mallolas, M. Laguno, 2012, PloS one.

Dose‐Finding Study of Once‐Daily Indinavir/Ritonavir Plus Zidovudine and Lamivudine in HIV‐Infected Patients

Á. Soriano, A. Cruceta, T. Pumarola, 2000, Journal of acquired immune deficiency syndromes.

Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis

Felipe García, J. Miro, J. Gatell, 2017, BMC Nephrology.

Hepatic steatosis with stavudine in HIV/hepatitis C virus co-infection.

J. Gatell, J. Mallolas, M. Laguno, 2005, AIDS.

Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years.

D. Podzamczer, J. Mallolas, M. Leal, 2012, Current HIV research.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

B. Clotet, L. Ruiz, C. Vidal, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Increasing of New CA-MRSA Infections Detected in people living with HIV Who Engage in Chemsex in Barcelona: An Ambispective Study

Á. Soriano, J. Mallolas, J. Blanco, 2023, Infectious Diseases and Therapy.

Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.

J. Mallolas, J. Blanco, M. Laguno, 2023, The Journal of antimicrobial chemotherapy.

Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults

J. Gatell, J. Mallolas, F. Vidal, 2008, AIDS.

Multi-omics in HIV: searching insights to understand immunological non-response in PLHIV

E. Negredo, J. Mallolas, S. Fernández-Arroyo, 2023, Frontiers in immunology.

Guillain-Barré-like syndrome as a rare presentation of severe primary HIV-infection.

J. Mallolas, J. Ambrosioni, E. Rabadán Pejenaute, 2021, Enfermedades infecciosas y microbiologia clinica.

Guillain-Barré-like syndrome as a rare presentation of severe primary HIV-infection

J. Mallolas, J. Ambrosioni, E. Rabadán Pejenaute, 2021, Enfermedades Infecciosas y Microbiología Clínica.

[Disseminated cryptococcosis in patients with AIDS. Prognostic factors of poor outcome].

Á. Soriano, J. Miro, J. Gatell, 1999, Medicina clinica.

Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003).

Felipe García, M. Plana, M. Arnedo, 2006, Enfermedades infecciosas y microbiologia clinica.

Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

C. Tural, J. Mallolas, C. Quereda, 2009, Hepatology.

Subclinical cardiovascular disease in patients starting contemporary protease inhibitors

J. Mallolas, M. Loncá, M. Camafort, 2018, HIV medicine.

Pharmacokinetic Assessment of Nevirapine and Metabolites in Human Immunodeficiency Virus Type 1-Infected Patients with Hepatic Fibrosis

T. Macgregor, J. Mallolas, A. M. Cammett, 2009, Antimicrobial Agents and Chemotherapy.

Ceftriaxone Monotherapy for Severe Bacteremic Infections

J. Mallolas, J. Pachón, J. Aguado, 1989 .

Prophylaxis of Pneumocystis Pneumonia and Toxoplasmosis

J. Gatell, J. Mallolas, L. Zamora, 1996, Annals of Internal Medicine.

Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients [abstract LB-37]

J. Mallolas, M. Laguno, J. Slim, 2012 .

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

J. Mallolas, C. Quereda, F. Pulido, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

D. Podzamczer, J. Mallolas, J. Losa, 2021, Trials.

LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

M. Bickel, P. Cahn, J. Mallolas, 2018, Open Forum Infectious Diseases.

Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.

J. Mallolas, M. Laguno, J. Ambrosioni, 2023, The Journal of antimicrobial chemotherapy.